Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MGAM | O43451 | 7/20 | 0.37 |
| ▸ | GAA | P10253 | 7/20 | 0.37 |
| ▸ | SI | P14410 | 7/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 7/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | CTSA | P10619 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL363538 | 0.88 | TDP1 (0.38) | TDP1MGAMGAASIMGAM2 | |
| SCHEMBL370596 | 0.83 | CYP1A2 (0.40) | TDP1POLBCTSAALDH1A1 | |
| SCHEMBL364325 | 0.81 | CTSA (0.41) | TDP1CTSA | |
| SCHEMBL1390463 | 0.81 | MGAM (0.46) | MGAMGAASIMGAM2EPHX2 | |
| SCHEMBL371201 | 0.77 | MGAM (0.53) | MGAMGAASIMGAM2EPHX2 | |
| SCHEMBL371137 | 0.76 | EPHX2 (0.50) | MGAMGAASIMGAM2EPHX2 | |
| SCHEMBL364504 | 0.74 | GPBAR1 (0.40) | CTSA | |
| SCHEMBL363154 | 0.73 | HPGD (0.35) | POLBCTSAALDH1A1 | |
| SCHEMBL370006 | 0.73 | CYP2C9 (0.38) | POLB | |
| SCHEMBL362689 | 0.73 | TDP1 (0.38) | TDP1MGAMGAASIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593426-B1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | HOFFMANN LA ROCHE (CH) | 2014-08-20 | — | — | EP | disclosed |
| US-8765730-B2 | 1-hydroxyimino-3-phenyl-propanes | Hoffmann-La Roche Inc (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2593426-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012007365-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | GPBAR1, GPR119, ADRB1 | TDP1 2650/4885POLB 2940/4885MGAM 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.